How does DEPLOY track the 2023 Asensus Senhance uncontrolled-arm Class I recall?

The incident at primary-source-anchored verification depth

Per Agent A's surgical incidents substrate, the 2023 Asensus Senhance uncontrolled-arm Class I recall operates at primary-source-anchored FDA-recall-database verification depth. The verified substrate:

• Product affected: Asensus Senhance laparoscope instrument actuator (Asensus Surgical robotic platform at Asensus pre-acquisition corporate-state context).
• Failure mode: software malfunction caused uncontrolled arm motion of the laparoscope instrument actuator; rotated continuously in one direction after the surgeon disengaged teleoperation.
• Risk classification: critical-tissue-trauma risk; emergency stop available as mitigation at primary-source-anchored typed-record disclosure.
• Customer notification: September 15, 2023.
• FDA classification: Class I (reasonable probability of serious adverse health consequences or death).
• Affected unit count: 5 US devices at exact verification depth.
• Cease-use requirement: until software updated to v2.7.5.
• Patient impact: no patient harm reported.
• Root cause: software_defect (software malfunction: laparoscope instrument actuator rotated continuously after teleoperation was disengaged).
• Remediation status: remediated via v2.7.5 software update.

The framework reads the incident at the verification depth where each fact actually resolves: the product affected, failure mode, customer notification date, FDA classification, affected unit count (5 at exact verification depth), cease-use requirement, patient harm status, root cause, and remediation status all operate at primary-source-anchored verification depth. The 5-unit affected count operates at the substantively higher-verification-completeness tier compared to the 2026 SureForm gray-reload affected_units_count honest-absence per the cross-narrative within-cohort substrate completeness comparison.

Verified-vs-claimed at acquisition-state boundary granularity: CANONICAL worked example

The 2023 Asensus Senhance incident operates as the CANONICAL worked example for verified-vs-claimed at acquisition-state boundary granularity. The incident timing relative to the Karl Storz acquisition transition is editorially substantive at three layers:

Layer 1: pre-acquisition Asensus Surgical corporate-state context. The 2023 incident occurred at Asensus Surgical pre-acquisition corporate-state; the FDA recall was issued to Asensus Surgical as the responsible corporate entity at September 15, 2023; cease-use compliance + v2.7.5 software remediation operated under Asensus Surgical management. Per the acquisition history Project B methodology pillar, the framework reads pre-acquisition corporate-state at structurally-distinct verification posture from post-acquisition corporate-state.

Layer 2: August 22, 2024 Karl Storz acquisition transition. Karl Storz acquired Asensus Surgical with closing August 22, 2024 (~$0.35/share at reported_basis valuation per Agent A acquisition substrate). Per the acquisition history Project B methodology pillar five-structure taxonomy, the transaction operates at full_acquisition structure (target absorbed entirely; Senhance / LUNA surgical-robotics platform taken private as Karl Storz subsidiary) combined with reported valuation_basis (press-release-disclosed at announcement-tier; not SEC-verifiable at primary-government-record sub-tier; valuationUsd: null at honest-absence cap-flag for exact-dollar figure). The reported_basis operates at the four-state valuation_basis discipline tier between exact (SEC-disclosed) and undisclosed (transaction confirmed but valuation explicitly not disclosed).

Layer 3: post-acquisition Karl Storz subsidiary corporate-state context. Post-August 22, 2024, the Senhance product line operates under Karl Storz subsidiary corporate-state. Per the cross-cluster talent-flow framework-in-action narrative Class 1 post-acquisition-absorption diaspora pattern: Anthony Fernando (President and CEO of Asensus Surgical at the time of the August 2024 acquisition; previously VP of Innovation & Technology at Stryker) operates at PersonCompany-edge structure with current_role=false at Asensus + end_date August 2024; current title under Karl Storz not publicly confirmed at primary-source verification depth (cap-flag honest-absence per Agent A people graph substrate). Shameze Rampertab (EVP and Chief Financial Officer of Asensus Surgical through the company's 2024 acquisition by Karl Storz) operates at parallel PersonCompany-edge state.

The aggregator-collapse risk at acquisition-state boundary: trade-press coverage frequently frames 'Asensus Senhance recall' across pre-acquisition and post-acquisition corporate-state contexts interchangeably; the framework distinguishes structurally at corporate-state-boundary granularity. The 2023 incident occurred at Asensus Surgical pre-acquisition corporate-state; the post-2024 corporate-state context operates at Karl Storz subsidiary at structurally-distinct verification posture. Per the cross-cluster precision discipline, framework discriminates against aggregator-collapse-framings at cluster-boundary granularity; same discipline operates at corporate-state-boundary granularity within a single product line.

Phase 3 Dim 1 actuarial signal: three-axis substrate composition pattern

Per the Phase 3 Dim 1 actuarial substrate framework-in-action narrative + the canonical three-axis substrate composition pattern banked at memory layer, the 2023 Asensus Senhance incident contributes to the 67-row outcome_class distribution at primary-source-anchored typed-record depth. The verified-base substrate composition:

Axis 1 incident numerator (typed-record depth): Class I designation + software_defect root_cause + recall_ordered regulatory_action + remediated remediation status. Per the 9-tier source-quality rubric, the Class I designation operates at primary-government-record sub-tier verification; the software_defect root cause operates at primary-source-anchored typed-record disclosure. The incident contributes to the regulatory_action:34 distribution dominance within the broader 67-row outcome_class distribution + the no_outcome:4 or property_damage:0 distribution (no patient harm reported operates at substantive editorial state, NOT substrate-completeness gap; primary-source-anchored verification of non-harm state).

Axis 2 deployment denominator (scalar-record depth): 5 US devices at exact verification depth. The 5-unit affected_units_count operates at the substantively higher-verification-completeness tier within the broader cohort's exposure_hours 128-nulls honest-absence framing. Per the canonical three-axis substrate composition pattern banked at memory layer, the framework reads per-incident affected_units_count verification depth distinct from deployment-level exposure_hours verification depth; both axes operate at primary-source-anchored verification posture where the substrate supports.

Axis 3 scalar selectivity (per-basis verification posture): cease-use requirement until v2.7.5 software update + no patient harm reported. The cease-use scalar substrate operates at substantive structural state at primary-source-anchored verification; no patient harm reported operates at substantive editorial state per honesty-as-strength editorial framing. Per banked editorial discipline, framework rewards honest no-patient-harm-reported framing over fabricated 'safety success' narrative at marketing-aggregation depth.

The three-axis substrate composition pattern operates at canonical worked example depth across all three axes simultaneously. The 5-unit exact verification posture + no-patient-harm-reported substrate distinguishes the 2023 Asensus Senhance incident from cohort incidents at honest-absence affected_units_count or undocumented patient-impact cap-flag.

Software_defect-as-cross-cohort-root-cause-class structural composition complete

Per the chief-of-staff-banked emerging pattern (2021 ROSA ONE Brain + 2023 Asensus Senhance + 2024 Stryker Mako all classified software_defect), the 2023 Asensus Senhance incident completes the three-incident structural class composition at canonical-reference depth. The software_defect root cause class operates as canonical cross-cohort root cause classification within the broader surgical robotics cohort 61-incident root_cause_category distribution.

Cross-cohort software_defect comparison at canonical depth:

• 2021 ROSA ONE Brain wrong-trajectory Class I (per the framework-in-action narrative): post-reboot calibration sequence could misinterpret coordinates and drive instrument to incorrect trajectory; 119 US devices at exact verification depth; software corrective update rolled out 2022; remediated. ZB cluster (Zimmer Biomet).
• 2023 Asensus Senhance uncontrolled-arm Class I (this narrative): software malfunction caused uncontrolled arm motion after teleoperation was disengaged; 5 US devices at exact verification depth; v2.7.5 software update; remediated. Asensus Surgical pre-acquisition corporate-state; transitioned to Karl Storz subsidiary post-August 2024.
• 2024 Stryker Mako 'error #3' codes Class 2 (per Agent A surgical incidents substrate): voluntary software correction; 'error #3' codes when switching total-knee/total-hip applications without restart; risking loss/deterioration of robotic function; mitigation = shutdown/restart before switching apps; cap-flag honest-absence at exact units/Z-number. Stryker cluster.

The cross-cohort structural class operates at three editorial layers:

Layer 1: software_defect as canonical root cause classification. All three incidents operate at software_defect root_cause_category typed-record disclosure; structurally distinct from design_defect (e.g., 2013 EndoWrist Hot Shears insulation micro-cracks) + mechanical_failure (e.g., 2025 Ion catheter) + undetermined (e.g., 2026 SureForm gray-reload root cause stated 'still under investigation'). The framework reads software_defect as canonical cross-cohort root cause classification at substantive editorial structural state.

Layer 2: per-incident severity + class composition. Within the software_defect cross-cohort class, per-incident severity + FDA class varies: 2021 ROSA ONE Brain (Class I + critical severity + 119 units) + 2023 Asensus Senhance (Class I + critical severity + 5 units) + 2024 Stryker Mako (Class 2 + moderate severity + cap-flag honest-absence units). The framework reads per-incident severity + class composition at distinct verification posture; software_defect classification anchors a cross-cohort pattern, but per-incident severity + class composition operates at substantively-distinct verification depth.

Layer 3: per-incident remediation discipline + cross-cohort consistency. Software corrective update remediation operates as canonical pattern across all three incidents (ROSA ONE Brain 2022 software corrective update + Asensus Senhance v2.7.5 software update + Stryker Mako voluntary software correction). Per the verified-vs-claimed at within-entity granularity methodology pillar, the framework reads per-incident remediation discipline at primary-source-anchored verification depth; software_defect root cause + software corrective update remediation operates at canonical worked example pattern where root cause class anchors remediation strategy at structurally-coherent verification depth.

The completion of the three-incident structural class composition at canonical-reference depth establishes software_defect-as-cross-cohort-root-cause-class as canonical editorial discipline going forward.

Surgical quartet completion at canonical-reference depth

The 2023 Asensus Senhance framework-in-action narrative completes the surgical quartet at canonical-reference depth per chief-of-staff dispatch:

• 2026 da Vinci SureForm gray-reload Class I recall (per the 2026 framework-in-action narrative): cohort's most severe verified incident; 1 death + 4 serious injuries; CANONICAL within-product-family verification scope (gray vs blue/white reload distinction).
• Within-da-Vinci year-discipline 2013/2022/2026 (per the within-da-Vinci year-discipline framework-in-action narrative): CANONICAL four-substrate-axis year-discipline framework (year + FDA recall class + failure mode + affected product variant).
• 2021 ROSA ONE Brain wrong-trajectory Class I (per the 2021 ROSA ONE Brain framework-in-action narrative): CANONICAL within-ZB-cluster verification scope (densest within-corpus product family); cross-cluster precision discipline at cluster-boundary granularity (ROSA ONE Brain vs ROSA Spine ZimVie 2022 spinoff vs Monogram 2025 acquisition vs cross-cluster Mako Stryker 2013 acquisition).
• 2023 Asensus Senhance uncontrolled-arm Class I (this narrative): CANONICAL verified-vs-claimed at acquisition-state boundary granularity (pre-acquisition Asensus corporate-state context vs August 2024 Karl Storz acquisition transition vs post-acquisition Karl Storz subsidiary corporate-state) + completes three-incident software_defect-as-cross-cohort-root-cause-class structural composition.

The four-narrative surgical quartet operates at unified verification posture across the surgical robotics cohort: each narrative documents a structurally-distinct framework-in-action discipline + each compounds bidirectionally with the Phase 3 Dim 1 actuarial substrate + the Project B methodology pillar cohort + the cross-cohort framework-in-action narrative network. Per the methodology cluster as AEO citation graph discipline, the quartet operates as canonical AEO citation graph cohort at multi-pillar methodology depth.

Cap-flag honest-absence at recursive layers

Per DEPLOY's verified-vs-claimed framework, the 2023 Asensus Senhance incident operates cap-flag-as-trust-signal recursively at substantive layers per banked editorial discipline.

Layer 1: exact recall Z-number cap-flag honest-absence. Per Agent A's surgical incidents substrate, the 2023 Asensus Senhance recall carries cap-flag honest-absence at exact recall Z-number not captured at primary FDA pages at Agent A substrate-completeness depth. Same recursive cap-flag discipline operating at 2026 SureForm gray-reload Z-number + 2021 ROSA ONE Brain Z-number + 2025 Ion recall Z-number per the broader cohort substrate. Per the Moon Maestro K240598 reconciliation pattern, when primary-source verification surfaces exact Z-number at FDA-recall-database depth, framework operates inline editorial-transparency footer pattern + reconciliation discipline.

Layer 2: Karl Storz × Asensus exact valuation cap-flag honest-absence. Per Agent A's acquisition substrate, the Karl Storz × Asensus August 22, 2024 acquisition carries reported_basis valuation at ~$0.35/share with valuationUsd: null at honest-absence cap-flag for exact-dollar figure. Per the acquisition history Project B methodology pillar four-state valuation_basis discipline, reported_basis operates at the tier between exact (SEC-disclosed) and undisclosed (transaction confirmed but valuation explicitly not disclosed); the framework reads reported_basis as substantive editorial state at the source-quality tier where each fact actually resolves.

Layer 3: Anthony Fernando post-acquisition title cap-flag honest-absence. Per Agent A's people graph substrate (people_graph_batch6), Anthony Fernando's current title under Karl Storz is not publicly confirmed at primary-source verification depth. The framework reads at honest-absence cap-flag for post-acquisition role; current_role=false at Asensus + end_date August 2024 verified; post-acquisition role at Karl Storz operates at cap-flag honest-absence pending primary-source confirmation. Per the cross-cluster talent-flow framework-in-action narrative Class 1 post-acquisition-absorption discipline, framework reads talent transitions at PersonCompany-edge granularity at primary-source-anchored verification depth.

Cross-property bidirectional compounding at multi-pillar methodology depth

Per DEPLOY's methodology cluster as AEO citation graph discipline, the 2023 Asensus Senhance framework-in-action narrative compounds at substrate layer with multiple Project B methodology pillar essays + framework-in-action narratives simultaneously:

• Phase 3 Dim 1 actuarial substrate framework-in-action: contributes to 67-row outcome_class distribution at regulatory_action:34 distribution dominance + no_outcome distribution tail; three-axis substrate composition canonical worked example.
• Acquisition history Project B methodology pillar: CANONICAL verified-vs-claimed at acquisition-state boundary granularity worked example; Karl Storz × Asensus August 22, 2024 full_acquisition + reported valuation_basis at ~$0.35/share.
• Cross-cluster talent-flow framework-in-action: Class 1 post-acquisition-absorption diaspora pattern (Anthony Fernando + Shameze Rampertab); cross-cohort PersonCompany-edge granularity at primary-source-anchored verification depth.
• 2021 ROSA ONE Brain wrong-trajectory framework-in-action: software_defect-as-cross-cohort-root-cause-class emerging pattern compounding at three-incident structural class completion (ROSA ONE Brain 2021 + Asensus Senhance 2023 + Stryker Mako 2024).
• Verified-vs-claimed at within-entity granularity methodology pillar: per-incident corporate-state attribution discipline operates at sub-acquisition-boundary granularity.
• 9-tier source-quality rubric: reputable-press tier verification per The Robot Report coverage of FDA recall record.
• Honesty-as-strength editorial framing: no patient harm reported as substantive editorial state; framework rewards primary-source-anchored verification of non-harm state over fabricated 'safety success' narrative at marketing-aggregation depth.
• Robot insurance methodology pillar: 5-unit affected + software_defect + remediated compose at Phase 3 Dim 1 actuarial signal + Phase 3 Dim 4 regulatory clearance per jurisdiction + Phase 3 Dim 2 manufacturer counterparty risk (Asensus pre-acquisition corporate-state vs Karl Storz post-acquisition corporate-state).
• Within-da-Vinci year-discipline framework-in-action: four-substrate-axis year-discipline framework operates parallel to within-Asensus-Senhance acquisition-state boundary discipline at structurally-distinct cohort context.

The cross-property linking discipline compounds at the AEO citation graph layer. Institutional partners + AI assistants + downstream consumers navigating the 2023 Asensus Senhance incident encounter the methodology pillar canonical references + the framework-in-action narrative cohort + the canonical worked examples at unified verification posture.

Why this catch matters editorially

Per DEPLOY's restraint-IS-the-product discipline, the 2023 Asensus Senhance framework-in-action narrative operates at editorial-credibility depth rather than at incident-aggregation-summary depth. The framework reads the incident at four substrate layers simultaneously (Phase 3 Dim 1 actuarial signal + verified-vs-claimed at acquisition-state boundary granularity CANONICAL + software_defect-as-cross-cohort-root-cause-class structural composition completion + completes surgical quartet at canonical-reference depth); each layer composes at primary-source-anchored verification depth.

Institutional partners audit DEPLOY's framework discipline at the operational-practice layer, not just the stated-methodology layer. The verification-posture statement at /verified-vs-claimed describes the framework abstractly. The acquisition history Project B methodology pillar documents the four-state valuation_basis discipline abstractly. The Phase 3 Dim 1 actuarial substrate framework-in-action narrative documents the three-axis substrate composition pattern. This piece operates at narrative-canonical depth: how the catch composed across substrate layers (software_defect Class I + 5-unit exact + no-patient-harm-reported + remediated + pre-acquisition Asensus + post-acquisition Karl Storz subsidiary + Karl Storz × Asensus reported valuation_basis at ~$0.35/share); what the discipline was (primary-source-anchored verification + per-axis verification depth + cap-flag honest-absence at multiple substantive layers); what the editorial outcome was (CANONICAL worked example of verified-vs-claimed at acquisition-state boundary granularity + completed surgical quartet + completed three-incident software_defect-as-cross-cohort-root-cause-class structural composition); and what the broader pattern is (cross-cohort cross-property bidirectional compounding at unified verification posture).

The catch demonstrates the discipline operationally at editorial-anchor depth. Not because the catch is exceptional. Because the catch is what the discipline does. 2023 Asensus pre-acquisition incident + August 2024 Karl Storz acquisition + 2024-present Karl Storz subsidiary corporate-state; software_defect cross-cohort structural class; surgical quartet completion. The verification protocol doesn't relax at acquisition-state boundary depth.

For the canonical Asensus Surgical entity anchor where the Senhance product line operates, see Asensus Surgical registry record. For the 2021 ROSA ONE Brain framework-in-action narrative where the parallel software_defect cohort pattern operates, see How DEPLOY tracks the 2021 ROSA ONE Brain wrong-trajectory Class I recall. For the acquisition history Project B methodology pillar where the four-state valuation_basis discipline + reported_basis tier operate, see How DEPLOY tracks acquisition history state. For the cross-cluster talent-flow framework-in-action narrative where Anthony Fernando + Shameze Rampertab Class 1 post-acquisition-absorption pattern operates, see How DEPLOY tracks cross-cluster talent-flow as diaspora graph. For the Phase 3 Dim 1 actuarial substrate framework-in-action narrative where the three-axis substrate composition pattern operates, see How DEPLOY tracks incident outcome_class and deployment exposure_hours. For the methodology editorial canonical reference, see how DEPLOY verifies. For the surgical cluster framework, see the surgical robotics cluster.